A Phase 1, Open-label, Randomized, Three-period, Six-sequence Crossover Study in Healthy Adult Subjects to Evaluate the Bioavailability of an Oral Suspension Formulation Relative to the Tablet Formulation of Apremilast and to Assess the Effect of Food on the Pharmacokinetics of the Oral Suspension Formulation

Trial Profile

A Phase 1, Open-label, Randomized, Three-period, Six-sequence Crossover Study in Healthy Adult Subjects to Evaluate the Bioavailability of an Oral Suspension Formulation Relative to the Tablet Formulation of Apremilast and to Assess the Effect of Food on the Pharmacokinetics of the Oral Suspension Formulation

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Mar 2016

At a glance

  • Drugs Apremilast (Primary)
  • Indications Plaque psoriasis
  • Focus Pharmacokinetics
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 25 Mar 2016 Planned number of patients changed from 36 to 34 as reported by ClinicalTrials.gov.
    • 25 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Feb 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top